Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients
- 1 December 2002
- journal article
- pediatric critical-care
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 30 (12) , 2752-2756
Abstract
Objective To determine if propylene glycol accumulates in children receiving continuous lorazepam infusion and, if accumulation occurs, to determine if it is associated with significant laboratory abnormalities. Design Prospective study. Setting A tertiary care pediatric intensive care unit. Patients Eleven intubated pediatric intensive care patients receiving continuous lorazepam infusion for sedation. Interventions Propylene glycol accumulation was determined by comparing concentrations at baseline, after 48 hrs, and at end of therapy. Laboratory abnormalities were determined by comparing serum lactate and osmolar gap at baseline, after 48 hrs, and at end of therapy. Correlation between the cumulative dose of lorazepam received and the propylene glycol concentration measured at the end of therapy was determined. Measurements and Main Results Patients aged 1–15 months were studied. Lorazepam infusion rates ranged from 0.1 to 0.33 mg·kg−1·hr−1 and lasted 3–14 days. Propylene glycol accumulated significantly in patients receiving continuous infusion of lorazepam. The propylene glycol concentration increased during the study from 86 ± 93 μg/mL at baseline to 763 ± 660 μg/mL at the end of the study (p = .038). A statistically significant correlation between the cumulative dose of lorazepam received and propylene glycol concentration at the end of therapy was demonstrated (r2 = .65, p < .005). However, the propylene glycol accumulation was not associated with significant laboratory abnormalities. Neither serum lactate concentrations nor osmolar gap were significantly elevated over baseline. Conclusion Propylene glycol accumulated significantly in pediatric intensive care patients receiving continuous lorazepam infusion, and propylene glycol concentration correlated with the cumulative lorazepam dose the patient received. However, significant laboratory abnormalities due to propylene glycol accumulation were not observed.Keywords
This publication has 21 references indexed in Scilit:
- Osmolar Gap Metabolic Acidosis in a 60-Year-Old Man Treated for Hypoxemic Respiratory FailureChest, 2000
- Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusionCritical Care Medicine, 2000
- A Cost-Effective and Volume-Sparing Strategy for Continuous Benzodiazepine InfusionsCritical Care Medicine, 1997
- The Effect of ICU Sedation Guidelines and Pharmacist Interventions on Clinical Outcomes and Drug CostAnnals of Pharmacotherapy, 1997
- Comment: Possible Toxicity from Propylene Glycol in Lorazepam InfusionAnnals of Pharmacotherapy, 1997
- Lorazepam and midazolam in the intensive care unitCritical Care Medicine, 1996
- Polyethylene Glycol Nephrotoxicity Secondary to Prolonged High-Dose Intravenous LorazepamAnnals of Pharmacotherapy, 1995
- Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unitCritical Care Medicine, 1995
- Osmol gaps revisited: Normal values and limitationsJournal of Toxicology: Clinical Toxicology, 1993
- Propylene glycol-induced side effects during intravenous nitroglycerin therapyIntensive Care Medicine, 1988